Synergistic Effect of YK-4-279 and Paclitaxel on A549 Cell Line
Lung cancer, among all cancer types around the world, is listed as the major cause of death with high mortality rate. ERG transcription factor has an important role in the Epithelial Mesenchymal Transition (EMT), which is one of the most important mechanisms in lung cancer progression. It is known t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-12-01
|
| Series: | Proceedings |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2504-3900/2/25/1588 |
| Summary: | Lung cancer, among all cancer types around the world, is listed as the major cause of death with high mortality rate. ERG transcription factor has an important role in the Epithelial Mesenchymal Transition (EMT), which is one of the most important mechanisms in lung cancer progression. It is known that a small molecule inhibitor YK-4-279 is a potential inhibitor of ERG expression in prostate cancer. In this study, the possible synergistic effect of YK-4-279 and another anticancer drug, Paclitaxel is analysed in non-small cell lung cancer (NSCLC) cell line, A549. |
|---|---|
| ISSN: | 2504-3900 |